The relationship between the pharmacokinetics of gliclazide and its antidiabetic efficacy were evaluated on the basis of experimental determination of changes with time in the plasma levels of this antidiabetic agent and those of glucose. The experiment included rats with both initial normal glycaemia and alloxan-induced hyperglycaemia (glycaemia increased by a minimum of 30%). Pharmacokinetic and pharmacodynamic parameters were examined in the interval of 30 to 180 min after p.o. administration of a single dose of 25 mg/kg of gliclazide. The drug was administered on day 4, following a single i.v. dose of either 50 mg/kg of alloxan (hyperglycaemic group) or the injection vehicle (control group). Even though the biological availability of gliclazide was similar in both normoglycaemic and hyperglycaemic animals, the gliclazide-induced hypoglycaemizing response was not uniform: until 60 min, the decrease of glycaemia was smaller in animals with alloxan hyperglycaemia (23% decrease at 60 min) in contrast to the normoglycaemic animals (36% decrease at 60 min), at later times, the intensity of this hypoglycaemizing effect of gliclazide persisted in the hyperglycaemic animals, while in the normoglycaemic ones, a reversal of the hypoglycaemizing effect occurred. Copyright (c) 2007 John Wiley & Sons, Ltd.
- MeSH
- Alloxan administration & dosage toxicity MeSH
- Administration, Oral MeSH
- Time Factors MeSH
- Financing, Organized MeSH
- Gliclazide pharmacokinetics blood therapeutic use MeSH
- Hyperglycemia drug therapy chemically induced blood MeSH
- Hypoglycemic Agents administration & dosage pharmacokinetics therapeutic use MeSH
- Injections, Intravenous MeSH
- Insulin blood MeSH
- Blood Glucose metabolism MeSH
- Rats MeSH
- Area Under Curve MeSH
- Rats, Wistar MeSH
- Chromatography, High Pressure Liquid MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Male MeSH
- Animals MeSH
